



MINUTES OF EXTRAORDINARY GENERAL MEETING APRIL 2025

On Wednesday 23 April 2025 at 10.00 AM (CET the Extraordinary General Meeting of Curasight A/S (“Curasight” or the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.

The Extraordinary General Meeting was convened with the following agenda:

Agenda

1. Proposals from the Board of Directors

- 1.1 Extension and increasement of authorisations for the Board of Directors to increase the share capital
 - a. Extension and increasement of authorisations for the Board of Directors to increase the share capital with pre-emption rights
 - b. Extension and increasement of authorisation for the Board of Directors to increase the share capital without pre-emption rights
 - c. Amendment of the total amount with which the share capital may be increased by utilization of the authorizations in items 1.1a and 1.1b.
- 1.2 Authorisation for the Board of Directors to issue warrants
- 1.3 Authorisation to the chairman of the meeting

The Board of Directors had appointed attorney Ulrik Bangsbo Hansen, as Chairman of the Extraordinary General Meeting in accordance with Article 9.1 of the Company's Articles of Association.

The Chairman of the Meeting presented the legal basis for convening the Extraordinary General Meeting set out in the Danish Companies Act and the Company's Articles of Association.

Based on the foregoing, the Chairman of the Meeting stated that the Extraordinary General Meeting had been duly and lawfully convened and that the Extraordinary General Meeting was legally competent to transact the items comprised by the agenda of the Extraordinary General Meeting.

At the Extraordinary General Meeting, a share capital of nominal DKK 568,475,65 and 11,358,323 votes was represented by proxy, constituting approximately 53,75% of the Company's total share capital of nominally DKK 1,057,444.00 and the total number of votes of 21,148,880.00.



1. Proposals from the Board of Directors

The Chairman of the Meeting began by noting that the Extraordinary General Meeting was to consider three proposals, including three sub-proposals from the Board of Directors, and that these would be presented separately.

1.1 Extension and increase of authorisations for the Board of Directors

The Board of Directors had proposed extending and increasing the authorisations for the Board of Directors by one (1) year, with a total nominal amount of DKK 100,000,000 for each authorisation. This extension ensures the provided authorisations encompass the planned rights issue as detailed in the press release dated 4 April 2025.

The Chairman of the Meeting noted that the sub-proposals would be presented separately.

- a. Extension and increase of authorisations for the Board of Directors to increase the share capital with pre-emption rights

The Board of Directors had proposed that the general meeting amends the authorisation provided to the Board of Directors in Article 5.1.1 of the Articles of Association (i) by extending the period with one (1) year, and (ii) by raising the share capital the Board is authorised to increase the company's share capital by up to a total nominal amount of DKK 100,000,000.

The Chairman of the Meeting presented the proposal from the Board of Directors and the suggested amendment to the Company's Articles of Association.

The proposal was unanimously adopted by all votes represented at the general meeting.

Consequently, article 5.1.1 of the Company's Articles of Association will be amended as follows:

5	Bemyndigelser	Authorisations
5.1	<i>Bemyndigelser til forhøjelse af aktiekapitalen</i>	<i>Authorisations to increase of the share capital</i>
5.1.1	<i>Selskabets bestyrelse er bemyndiget til i perioden til og med 21. marts 2029 ad en eller flere gange at forhøje selskabets aktiekapital med op til i alt nominelt kr. 100.000.000 aktier. Kapitalforhøjelser skal ske ved fuld kontant betaling og med fortegningsret for selskabets eksisterende aktionærer til en kurs fastsat af bestyrelsen, der kan være under markedskursen på tidspunktet for bestyrelsens beslutning.</i>	<i>Until and including 21 March 2029, the board of directors shall be authorised to increase the Company's share capital in one or more issues by up to a total nominal amount of DKK 100,000,000 shares. Capital increases must be paid up in full in cash with pre-emption right for the company's existing shareholders at a price determined by the board of directors, which may be below market price at the time of the decision of the board of directors.</i>



Any shares issued pursuant to the amended authorisation in clause 5.1.1 would still be subject Article 5.1.4 of the Articles of Association.

- b. Extension and increase of authorisations for the Board of Directors to increase the share capital without pre-emption rights

The Board of Directors had proposed that the general meeting amends the authorisation provided to the Board of Directors in Article 5.1.2 of the Articles of Association (i) by extending the period with one (1) year, and (ii) by raising the share capital the Board to increase the company's share capital by up to a total nominal amount of DKK 100,000,000.

The Chairman of the Meeting presented the proposal from the Board of Directors and the suggested amendment to the Company's articles of association.

The proposal was unanimously adopted by all votes represented at the general meeting.

Consequently, Article 5.1.2 of the articles of association will be amended as follows:

5.1.2 Selskabets bestyrelse er bemyndiget til i perioden til og med 21. marts 2029 ad en eller flere gange at forhøje selskabets aktiekapital med op til i alt nominelt kr. 100.000.000 aktier. Kapitalforhøjelser kan ske ved fuld kontant betaling, ved indbetaling af andre værdier end kontanter (apportindskud) eller ved konvertering af gæld eller som en kombination heraf. Kapitalforhøjelser skal ske til en kurs, der fastsættes af bestyrelsen, der kan være under markedskursen på tidspunktet for bestyrelsens beslutning, og skal ske uden fortegningsret for selskabets eksisterende aktionærer

Until and including 21 March 2029, the board of directors shall be authorised to increase the Company's share capital in one or more issues by up to a total nominal amount of DKK 100,000,000 shares. Capital increases may be carried out by payment in full of cash contribution, in-kind contribution of assets other than cash (contribution in kind) or through conversion of debt or a combination thereof. Capital increases shall be effected at a price to be determined by the board of directors, which may be below market price at the time of the decision of the board of directors, and without pre-emption right for the existing shareholders

Any shares issued pursuant to the amended authorisation in clause 5.1.2 is still subject Article 5.1.4 of the Articles of Association.

- c. Amendment of the total amount with which the share capital may be increased by utilisation of the authorisations in items 1.1a and 1.1b.

Following the approval of items 1.1a and 1.1b, the Board of Directors had proposed that the general meeting amend Article 5.1.3 which states with how much the total share capital can be increased under the authorisations in Article 5.1.1 and 5.1.2.

The Chairman of the Meeting presented the proposal from the Board of Directors and the suggested amendment to the Company's articles of association.

The proposal was unanimously adopted by all votes represented at the general meeting.



Consequently, article 5.1.3 of the Company's articles of association will be amended as follows:

- | | |
|---|--|
| <p>5.1.3 <i>Bemyndigelserne i pkt. 5.1.1 og 5.1.2 kan tilsammen ikke overstige nominelt kr. 100.000.000 aktier.</i></p> | <p>The authorisations set out in articles 5.1.1 and 5.1.2 cannot, in the aggregate, exceed a nominal amount of DKK 100,000,000 shares.</p> |
|---|--|

1.2 Authorisation for the Board of Directors to issue warrants

The Board of Directors had proposed that the general meeting authorises the Board of Directors to issue warrants for the purpose of obtaining financing for the Company i.e. the warrants can be provided to entities providing funding. The Board of Directors plans utilising the authorization to issue warrants to a third party lender backing the planned Rights Issue as detailed in the press release dated 4 April 2025 as part of the agreement with said third party investor.

Under the proposed authorisation, a total of up to 106,376,256 warrants may be allocated to (and subscribed for by) the participants with no consideration paid by the participants for subscribing the warrants.

The number of warrants allocated to a participant may be adjusted in the event of capital changes and other comparable matters.

The Chairman of the Meeting presented the proposal from the Board of Directors and the suggested amendment to the Company's Articles of Association.

The proposal was unanimously adopted by all votes represented at the general meeting.

This new authorisation will be included in a new Article 5.2.6 of the Company's articles of association worded as follows:

- | | |
|--|--|
| <p>5.2.6 <i>Selskabets bestyrelse er bemyndiget til af én eller flere gange i henhold til selskabslovens §155, jf. §169, at udstede op til 106.376.256 warrants i Selskabet med ret til tegning af op til i alt nominelt 5.318.812 kr. kapitalandele i Selskabet uden fortegningsret for de eksisterende kapitalejere i Selskabet til en kurs og fordeling, som fastlægges af bestyrelsen. Kursen kan være under markedskursen på tidspunktet for bestyrelsens beslutning.</i></p> | <p><i>The Company's board of directors is authorised, pursuant to s. 155 of the Danish Companies Act, cf., s. 169 thereof, in one or several instances, to issue up to a total of 106,376,256 warrants, which will entitle their holder(s) to subscribe for up to a total of nominally DKK 5,318,812 shares in the Company without pre-emption rights for the existing shareholders at a subscription price and allocation determined by the board of directors. The subscription price may be below the market price at the time of the decision of the board of directors.</i></p> |
|--|--|



Samtidig er bestyrelsen bemyndiget til at foretage den dertil hørende forhøjelse af Selskabets aktiekapital ad en eller flere omgange med nominelt 5,318,812 kr., eller et andet beløb som følge af eventuel regulering af antallet af udstedte warrants, antallet af kapitalandele, som de udstedte warrants giver ret til at tegne, og/eller tegningskursen i henhold til de til enhver tid gældende vilkår for de udstedte warrants.

Bemyndigelsen løber frem til 16. april 2030. Aktier udstedt i henhold til bemyndigelsen i dette pkt. 5.2.6 skal indbetales fuldt ud ved gældskonvertering eller kontant indskud, være omsætningspapirer, skal lyde på navn og noteres på navn i Selskabets ejerbog. Der gælder samme indskrænkninger i aktiernes omsættelighed, som gælder for de eksisterende aktier og ingen aktionær er forpligtet til at lade aktier indløse helt eller delvist.

Bestyrelsen er bemyndiget til at genanvende eller genudstede eventuelle bortfaldne ikke-udnyttede warrants, forudsat at genanvendelsen eller genudstedelsen finder sted inden for de vilkår og tidsmæssige begrænsninger, der fremgår af bemyndigelsen.

The Company's board of directors is also authorised to carry out any related share capital increases, in one or several instances, up to a total of nominally DKK 5,318,812 or such other amount as required following an adjustment of the number of warrants, the numbers of shares that issued warrants entitle the holder(s) to subscribe and/or the exercise price in accordance with the terms governing the issued warrants.

The authorization is valid until 16 April 2030. Shares issued pursuant to the authorization in this clause 5.2.6 must be paid up in full by conversion of debt or by cash payment, be negotiable instruments, be registered by name and be registered by the name of shareholders in the Company's shareholders' register. The same restrictions on transferability as those applying to the existing shares apply and no shareholder shall be obligated to have the shares redeemed partly or in full.

The board of directors is authorized to reuse or reissue any lapsed, non-exercised warrants, provided that such reuse or reissuance observes the terms, and the expiration date set out in this authorization.

1.3 Authorisation to the chairman of the meeting

The Chairman of the Meeting noted that the Board of Directors had proposed that the chairman of the meeting, with full right of substitution, be authorised to apply for registration of the resolutions passed and to make any such amendments thereto as the Danish Business Authority or other authorities may require or request as a condition for registration or approval, as well as to continuously make and apply for registration of linguistic and other non-substantive adjustments to the Company's Articles of Association.

The proposal was unanimously adopted by all votes represented at the general meeting.



With no further items on the agenda, the Chairman of the Extraordinary General Meeting thanked the shareholders for their participation in a well-conducted Extraordinary General Meeting and resigned as Chairman of the Meeting.

The Extraordinary General Meeting was adjourned at 10.30 AM CET.

Chairman of the Meeting

Signed by:


A82B0454143A43E...
Ulrik Bangsbo Hansen